WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 to be held ...

Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the ...

Dipti Mehta has worked as a Senior Application Scientist at Revvity since 2022. Her research in DNA and protein assay development with LabChip GX Touch technology has generated new commercial assays.

Revvity (NYSE:RVTY) is preparing to release its quarterly earnings on Monday, 2026-02-02. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Revvity ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

WALTHAM, Mass.--(BUSINESS WIRE)--#LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate ...

Life sciences company Revvity (NYSE:RVTY) reported in Q4 CY2025, with sales up 5.8% year on year to $772.1 million. The company’s full-year revenue guidance of $2.98 billion at the midpoint came in ...